GENEREX BIOTECHNOLOGY CORP: 10-Q filed 2016-07-22
What GENEREX BIOTECHNOLOGY CORP reported in its quarterly report filed 2016-07-22 (fiscal Q2 2016): 23 published measures, 57 facts as tagged in accession 0001607062-16-000920.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-07-22
- Fiscal period
- fiscal Q2 2016
- Accession
- 0001607062-16-000920 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GENEREX BIOTECHNOLOGY CORP filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 1,344,208 | USD | |
| At 2015-07-31 | 2,234,090 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 11,146,927 | USD | |
| At 2015-07-31 | 10,524,410 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 9,802,719 | USD | |
| At 2015-07-31 | -8,290,320 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 31,768 | USD | |
| At 2015-07-31 | 749,965 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | -47,390 | USD | 92 |
| 2015-08-01 to 2016-01-31 | -1,778,655 | USD | 184 |
| 2014-11-01 to 2015-01-31 | -511,916 | USD | 92 |
| 2014-08-01 to 2015-01-31 | -462,293 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-08-01 to 2016-01-31 | -698,419 | USD | 184 |
| 2014-08-01 to 2015-01-31 | -1,604,812 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-08-01 to 2016-01-31 | 2,952 | USD | 184 |
| 2014-08-01 to 2015-01-31 | 542 | USD | 184 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-08-01 to 2015-01-31 | -46,587 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | -374,259,918 | USD | |
| At 2015-07-31 | -372,481,263 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-08-01 to 2016-01-31 | -0.002 | USD/shares | 184 |
| 2014-08-01 to 2015-01-31 | 0.0001 | USD/shares | 184 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-08-01 to 2016-01-31 | -0.002 | USD/shares | 184 |
| 2014-08-01 to 2015-01-31 | 0.0001 | USD/shares | 184 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 1,938 | USD | |
| At 2015-07-31 | 2,869 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | -157,532 | USD | 92 |
| 2015-08-01 to 2016-01-31 | -1,475,111 | USD | 184 |
| 2014-11-01 to 2015-01-31 | -835,147 | USD | 92 |
| 2014-08-01 to 2015-01-31 | -1,743,616 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 36,944 | USD | |
| At 2015-07-31 | 801,205 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | 102,187 | USD | 92 |
| 2015-08-01 to 2016-01-31 | 199,910 | USD | 184 |
| 2014-11-01 to 2015-01-31 | 85,468 | USD | 92 |
| 2014-08-01 to 2015-01-31 | 167,202 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 8,537,216 | USD | |
| At 2015-07-31 | 8,018,833 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 1,305,326 | USD | |
| At 2015-07-31 | 1,430,016 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | 157,532 | USD | 92 |
| 2015-08-01 to 2016-01-31 | 1,475,111 | USD | 184 |
| 2014-11-01 to 2015-01-31 | 835,147 | USD | 92 |
| 2014-08-01 to 2015-01-31 | 1,743,616 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | 67,628 | USD | 92 |
| 2015-08-01 to 2016-01-31 | 245,198 | USD | 184 |
| 2014-11-01 to 2015-01-31 | 222,384 | USD | 92 |
| 2014-08-01 to 2015-01-31 | 630,680 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 870,325,348 | shares | |
| At 2015-07-31 | 825,496,238 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-01-31 | 803,650 | USD | |
| At 2015-07-31 | 808,737 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-11-01 to 2016-01-31 | 89,904 | USD | 92 |
| 2015-08-01 to 2016-01-31 | 1,229,913 | USD | 184 |
| 2014-11-01 to 2015-01-31 | 612,763 | USD | 92 |
| 2014-08-01 to 2015-01-31 | 1,112,936 | USD | 184 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-08-01 to 2016-01-31 | 123,106 | USD | 184 |
| 2014-08-01 to 2015-01-31 | 203,430 | USD | 184 |
Inspect the source
- Entity
- GENEREX BIOTECHNOLOGY CORP / CIK 0001059784
- Captured
- SEC response SHA-256
a8779b8c3aa8286320834b30d50af09999238cecacb9e7883d21e11477763a4d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001059784.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))